Quantcast
Home > Quotes > EYES
EYES

Second Sight Medical Products, Inc. Common Stock (EYES) Quote & Summary Data

$1.87
*  
0.09
5.06%
Get EYES Alerts
*Delayed - data as of Sep. 21, 2018  -  Find a broker to begin trading EYES now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    EYES After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 1.82 / $ 1.88
1 Year Target
5
Today's High / Low
$ 1.88 / $ 1.75
Share Volume
343,174
50 Day Avg. Daily Volume
235,585
Previous Close
$ 1.78
52 Week High / Low
$ 2.58 / $ 1.05
Market Cap
131,461,653
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.37

Intraday Chart

Shares Traded

Share Volume:
343,174
50 Day Avg. Daily Volume:
235,585

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.54

Trading Range

The current last sale of $1.87 is 78.10% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.88 $ 2.58
 Low: $ 1.75 $ 1.05

Company Description (as filed with the SEC)

Second Sight was founded in 1998 with a mission to develop, manufacture, and market prosthetic devices that are intended to create an artificial form of useful vision for blind individuals. Our principal offices are located in Sylmar, California, approximately 25 miles northwest of downtown Los Angeles. We also have an office in Lausanne, Switzerland, that manages our commercial and clinical operations in Europe, the Middle East and Asia. Our current product, the ArgusĀ® II System, treats outer retinal degenerations, such as retinitis pigmentosa, often referred to as RP. RP is a hereditary disease, affecting an estimated 1.5 million people worldwide including about 100,000 people in the United States. The disease causes a progressive degeneration of the light-sensitive cells of the retina, leading to significant visual impairment and ultimately blindness.  ... More ...  


Risk Grade

Where does EYES fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.78
Open Date:
Sep. 21, 2018
Close Price:
$ 1.87
Close Date:
Sep. 21, 2018

Consensus Recommendation

Analyst Info